

PTO/SB/08B (01-08)

Approved for use through 01/31/2008, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/574,018		
		Filing Date	December 1, 2006		
		First Named Inventor	DELLAIRE, Graham et al.		
		Art Unit	1645		
		Examiner Name			
Sheet		of		Attorney Docket Number	3206-276 LAB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	BIANCHINI M ET AL: "Specific oligobodies against ERK-2 that recognize both the..." Journal of Immunological Methods 1 June 2001, vol. 252, no.1-2, 1 June 2001, pages 191-197	
	4	GADGIL H ET AL: "Affinity purification of DNA-binding proteins." Journal of Biochemical and Biophysical Methods 30 Oct 2001, vol.49, no. 1-3, 30 Oct 2001, pages 607-624	
	5	GADGIL H ET AL: "Heparin elution of transcription..." Journal of Chromatography, Elsevier Science Publishers B.V. Amsterdam, NL, vol.848, no. 1-2, 2 July 1999, pgs 131-138	
	6	KLUG S J ET AL: "All you wanted to know about Selex" Molecular Biology Report, Kluwer Academic Publishers, Dordrecht, NL, vol. 20, no. 2, Jan 1994, pgs 97-107	
	7	RADRIZZANI M ET AL: "Development of Monoclonal Oligobodies and Chemically Synthesized Oligobodies" Medicina, Buenos Aires, AR, vol.60, no. SUPPL 2, 7 Aug 2000, pgs 55-60	
	8	ROMIG T S ET AL: "Aptamer affinity chroma..." Journal of Chromatography B: Biomedical Applications, Elsevier Science Publishers, NL, vol.731, no.2, 27 Aug 1999, pgs 275-284	
	9	SHEDD D ET AL: "Detection of Human Serum Antibodies To the BFRF3 Epstein-Barr..." Journal of Infectious Diseases, Chicago, IL, US, vol.175, no.5, Nov 1995, pgs. 1367-1370	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.